TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05027945: A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Sponsor: National Cancer Institute (NCI) · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT05027945 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05027945 Rescue Dossier →